| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
We clarified that the muscle expression of PD-L1 was involved in the pathogenesis of myasthenia gravis (MG).
The association between PD-L1 expression and clinical parameter was analyzed in a generalized additive model. It showed that MG symptoms were more severe when PD-L1 expression was inadequate. Consequently, we concluded that PD-L1 expression of MG muscle may be important factor for the pathogenesis of MG. In addition, we focused on the concentration of soluble PD-L1 (sPD-L1) in serum of MG and indicated that MG symptoms may be improved in cases with higher sPD-L1 concentrations.
These results were suggested that PD-L1 may have the possibility of a new therapeutic agent in the future.
|
